Ubs Group Ag Iveric Bio, Inc. Transaction History

Ubs Group Ag

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$26.24 - $39.63 $2.64 Million - $3.98 Million	-100,451 Reduced 90.59%	10,431 $410,000
Q1 2023 May 12, 2023	SELL	$18.67 - $24.56 $2.98 Million - $3.91 Million	-159,395 Reduced 58.97%	110,882 $2.7 Million
Q4 2022 Feb 08, 2023	BUY	$17.24 - $23.95 $3.22 Million - $4.48 Million	186,872 Added 224.05%	270,277 $5.79 Million
Q3 2022 Nov 10, 2022	SELL	$9.4 - $18.59 $1.1 Million - $2.18 Million	-117,189 Reduced 58.42%	83,405 $1.5 Million
Q2 2022 Aug 10, 2022	BUY	$9.12 - $18.9 $1.62 Million - $3.37 Million	178,060 Added 790.18%	200,594 $1.93 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $27,045 - $37,463	-2,226 Reduced 8.99%	22,534 $379,000
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $51,074 - $69,354	3,693 Added 17.53%	24,760 $414,000
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $6,009 - $14,875	-850 Reduced 3.88%	21,067 $342,000
Q2 2021 Aug 13, 2021	BUY	$5.69 - $7.17 $4,995 - $6,295	878 Added 4.17%	21,917 $138,000
Q1 2021 May 12, 2021	BUY	$5.08 - $6.89 $76,103 - $103,219	14,981 Added 247.29%	21,039 $130,000
Q4 2020 Feb 11, 2021	BUY	$5.65 - $7.66 $26,939 - $36,522	4,768 Added 369.61%	6,058 $42,000
Q3 2020 Nov 12, 2020	SELL	$4.01 - $6.29 $773 - $1,213	-193 Reduced 13.01%	1,290 $7,000
Q1 2020 May 01, 2020	BUY	$2.83 - $8.44 $2,830 - $8,440	1,000 Added 207.04%	1,483 $5,000
Q3 2019 Nov 14, 2019	SELL	$1.09 - $1.29 $218 - $258	-200 Reduced 29.28%	483 $1,000
Q2 2019 Aug 14, 2019	BUY	$1.21 - $1.48 $826 - $1,010	683 New	683 $1,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.